Pulmonary Arterial Hypertension: therapeutic pathways
Keyword(s):
Pulmonary arterial hypertension (PAH) is a severe disease characterized by the loss and obstructive remodeling of the pulmonary arterial wall, causing a rise in pulmonary arterial pressure and pulmonary vascular resistance, which is responsible for right heart failure, functional decline, and death. The main molecular pathways involved in drugs are available for the treatment PAH involve nitric oxide, endothelin 1 and prostacyclin. Although, this condition continues to be life-threatening, and its long-term treatment is expensive.
2016 ◽
Vol 311
(4)
◽
pp. R721-R726
◽
2003 ◽
Vol 108
(17)
◽
pp. 2066-2069
◽
2020 ◽
Vol 36
(6)
◽
pp. 921-928
2012 ◽
Vol 8
(1)
◽
pp. 71-77
◽